Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants

• Main Authors: Holger Scheible (Author), Martin Dyroff (Author), Annick Seithel‐Keuth (Author), Eleanor Harrison‐Moench (Author), Nadra Mammasse (Author), Andreas Port (Author), Angelika Bachmann (Author), Jennifer Dong (Author), Jan Jaap vanLier (Author), William Tracewell (Author), David Mitchell (Author)
• Format: Book
• Published: Wiley, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract The highly selective, covalent Bruton's tyrosine kinase inhibitor evobrutinib is under investigation for treatment of patients with multiple sclerosis (MS). Early clinical studies in healthy participants and patients with relapsing MS indicated that evobrutinib is well‐tolerated and ef...